← Sazabi Research

Humana (HUM): A Four-Star Reset Reprices the Medicare Advantage Story

The 2027 Star Ratings Upgrade That Turns a Star-Crossed 2026 Into a 2028 Earnings Story — Quick Take

📅 10 October 2026 #Healthcare#MedicareAdvantage#ManagedCare#NYSE

Market Cap

$51.9B

Revenue (TTM)

$145.7B

P/E (Fwd)

34.8x

Rev Growth

+18.3%

Why This Company Now

Healthcare was the dominant sector on the Sat 10 Oct US VolumeSurge (22 of 50 passing names vs 14 Technology and 6 Basic Materials), and Humana was the largest uncovered large-cap in that cluster and its biggest mover: +11.56% (+$44.75) to $431.87 (~$2.2B turnover, 5.0M shares, P/E ~41), third by turnover behind MRNA ($6.5B) and LITE ($5.8B) — the first already inside its 30-day window and the second outside the dominant sector. HK VolumeSurge Fri 9 Oct passed just 2/2,817 names (both far below the US$15B floor), so no HK signal applied.

Catalyst: CMS released the 2027 Medicare Advantage Part C & D Star Ratings on 8–9 Oct, and Humana announced that 95% of its MA members are now enrolled in plans rated 4.0 stars or above — exceeding its own goal and restoring the quality-bonus mechanics that drive revenue two years forward (2027 ratings → 2028 payments). Baird upgraded HUM to Outperform and lifted its price target to $596 from $390 (analyst Michael Ha), citing greater confidence the company can earn >$35 in adjusted EPS in 2028; Barclays also raised its target. UnitedHealth rallied ~4% on the same headline while CVS slipped, making this a Humana-specific repricing, not a blanket sector bid. Never previously covered in this series.

Financial Snapshot

Year	Revenue ($M)	Rev Growth	Op Margin	Net Income ($M)	EPS
FY2021	83,064	+7.7%	3.79%	2,933	22.67
FY2022	92,870	+11.8%	4.60%	2,806	22.08
FY2023	106,374	+14.5%	4.30%	2,489	20.00
FY2024	117,761	+10.7%	2.58%	1,207	9.98
FY2025	129,664	+10.1%	2.53%	1,188	9.84
TTM (Jun'26)	145,679	+18.3%	2.30%	1,279	10.59

FY2026 is Jan–Dec. Q2 2026 (reported 29 Jul): revenue $40,867M +26.2% YoY, operating income $1,416M and net income $694M / $5.73 per share — a clean swing from Q4 2025's –$583M operating / –$796M net loss, when the poor BY2026 Star Ratings hit. Insurance revenue is ~96% of the total, with CenterWell (primary care, home health, pharmacy) at ~$24.7B gross and growing faster. Balance sheet: $6.9B cash & investments vs $14.7B total debt (~$7.9B net debt, ~3.9x EBITDA); TTM free cash flow $1,949M (1.3% margin); dividend $3.54/yr (~0.82% yield; ex-div 30 Oct). Guidance: FY2026 adjusted EPS ≥$9.00 (affirmed) but GAAP EPS cut to ≥$6.52 from ≥$8.36, with individual MA membership tracking ~+25% over 2025. Valuation at $431.87 (9 Oct close; 120.1M shares): ~40.8x TTM, ~34.8x forward, ~26.6x FCF, ~0.36x sales, 2.70x book, PEG 1.68, beta 0.74; 52-week +44.9%, 50-DMA $388, 200-DMA $297, RSI 66.2. Next earnings: 6 November 2026, before market open.

Bull vs Bear

✅ Bull Case

The Star-rating reset is the whole ballgame, and it just flipped positive. 95% of MA members in 4.0+ plans for 2027 restores quality-bonus payments from 2028 — Baird's model goes from a ~$9 adjusted EPS trough in 2026 to >$35 by 2028, a ~4x runway the tape began repricing with Friday's +11.6%.
Scale plus visible membership momentum. TTM revenue $145.7B (+18.3%), Q2 revenue $40.9B (+26%) with a $1,416M operating profit, and 2026 individual MA membership guided to ~+25% YoY on improved retention — growth is landing before the bonus recovery arrives.
CenterWell builds a vertically integrated moat. The care-delivery segment (~$24.7B gross TTM, growing ~13% YoY) captures margin the pure-insurance peers hand to providers, and leverage is modest at ~$7.9B net debt / 3.9x EBITDA against a 0.74 beta.

🔴 Bear Case

2026 is a guided-down trough, and the payoff is two years out. GAAP EPS guidance was cut to ≥$6.52 from ≥$8.36 at Q2 precisely because the bad BY2026 ratings still bite — so the stock just re-rated on a 2028 number while 2026–2027 earnings stay depressed.
Paper-thin margins at an expensive multiple. Operating margin has compressed from 4.60% (FY22) to 2.30% TTM; at $431.87 the stock trades ~34.8x forward and ~26.6x FCF after a +45% 52-week run, sitting ~11% above its 50-DMA ($388) and ~45% above its 200-DMA ($297). Baird's $596 is the outlier, not the consensus.
Star ratings are annual and reversible — they just fell a year ago. Utilization/MLR and CMS rate policy remain the swing factors, plan exits continue into 2027, and ~$7.9B of net debt plus a token 0.82% dividend leave little buffer if medical costs re-accelerate.

Verdict

Humana has been rewritten in 48 hours from a broken-Medicare story into a quality-bonus recovery story: the 2027 four-star ratings plus ~25% membership growth give real substance to Baird's >$35 adjusted EPS in 2028, which is why a $596 target exists a day after a $390 one. But the tape has already paid for a chunk of it — +45% over a year, +11.6% in a single session, ~35x forward on trough earnings, and 2026 GAAP guidance just cut. The direction is credible; the entry is Friday's gap. More interesting on a pullback toward the mid-$300s / 50-DMA ($388) than chasing $432 into the 6 November Q3 print — and the whole thesis hinges on Star Ratings holding next October.

Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers (Humana IR/press releases, CMS Star Ratings releases, stockanalysis.com, Baird/Barclays notes, CNBC/Bloomberg/Benzinga coverage). All figures in USD unless stated; market data as of the 9 October 2026 close.